Daanish Hoda, MD
Hematology & Oncology · Salt Lake City, UTNPI 1043308380
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,702 of the $80,493 with a category attached, or 65.5%. 16 manufacturers reported payments, led by Johnson & Johnson at 40.8% of the total.
Across 82 payments — averaging $981.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$33K
- E.r. Squibb & Sons, L.L.C.$32K
- Amgen$7K
- Incyte Corporation$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Bristol Myers Squibb$900
- plus $376 from 10 others
Across 65 payments — averaging $43,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.9M
- Gilead$548K
- Regeneron$194K
- Pharmacyclics LLC, An Abbvie Company$125K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Janssen Scientific Affairs, LLC$3K
- plus $800 from 1 others
What the payments were for
- Consulting fees$16,44020%
- Speaking & faculty fees$52,70265%
- Travel & lodging$9,81212%
- Food & beverage$1,5392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $32,852 |
| E.r. Squibb & Sons, L.L.C. | 21 | $32,497 |
| Amgen | 3 | $7,139 |
| Incyte Corporation | 4 | $3,704 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,025 |
| Bristol Myers Squibb | 3 | $900 |
| Gilead | 1 | $149 |
| Novartis | 3 | $63 |
| Astellas Pharma US Inc | 3 | $46 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Merck | 1 | $19 |
| AbbVie | 1 | $18 |
| Sanofi | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,493 in reported general payments places this provider in the 85th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
- Anna ChalmersSalt Lake City$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.